期刊文献+

先天性心脏病肺动脉高压吸入NO的疗效观察 被引量:1

下载PDF
导出
摘要 目的 探讨吸入外源性 (NO)对先天性心脏病中重度肺动脉高压的治疗效果。 方法 对 14例中重度肺动脉高压的先天性心脏病术后病人 ,分别行右心导管检查 ,测定每例在基础状态下、吸入纯氧或一氧化氮时的血液动力学参数 ,并进行统计学分析。 结果  14例吸入一氧化氮、纯氧与基础状态比较 ,肺动脉平均压 (mPAP)两组之间存在显著差异 (P <0 0 5 ) ;主动脉平均压 (mSAP)则无明显差异 (P >0 0 5 ) ;肺循环阻力与体循环阻力之比均明显降低 (P <0 0 5 )。 结论 NO对先天性心脏病合并中重度肺动脉高压患者有一定治疗作用。
作者 申红亚 杨静
出处 《实用心脑肺血管病杂志》 2003年第5期292-293,共2页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
  • 相关文献

参考文献3

  • 1[1]Pepke Zaba J, Higenbotton TW, Dinh Xuan AT,et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet. 1991,338:1173 ~ 1174.
  • 2[2]Foubert L, Fleming B, Latimer R, et al. Safety guidelines for the use of nitric oxide. Lancet. 1992,339: 1615 ~ 1616.
  • 3[3]Robin E, Haddad, Vallet B. Inhaled nitric oxide in the properative period and revery. Ann Anesth Reanim, 2002,21: 581 ~ 590.

同被引文献37

  • 1Rosenzweig EB,Kerstein D,Barst RJ.Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects[J].Circulation,1999,99:1858-1865.
  • 2Kuo PC,Johnson LB,Plotkin JS,et al.Continuous intravenous infusion ofepoprostenol for the treatment of portopulmonary hypertension[J].Transplan-tation,1997,63:604-606.
  • 3Nunes H,Humbert M,Sitbon O,et al.Prognostic factors for survival in HIV-associated pulmonary arterial hypertension[J].Am J Respir Crit Care Med,2003,167:1433-1439.
  • 4Simonneau G,Barst RJ,Galiè N,et al.Continuous subcutaneous infusion oftreprostinil,a prostacyclin analogue,in patients with pulmonary arterial hyper-tension:a double-blind randomized controlled trial[J].Am J Respir Crit CareMed,2002,165:800-804.
  • 5Vachiéry JL,Hill N,Zwicke D,et al.Transitioning from Ⅳ epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension[J].Chest,2002,121:1561-1565.
  • 6Galiè N,Humbert M,Vachiéry JL,et al.Effects of beraprost sodium,an oral prostacyclin analogue,in patients with pulmonary arterial hypertension:a randomized,double-blind placebo-controlled trial[J].J Am Coll Cardiol,2002,39:1496-1502.
  • 7Barst RJ,McGoon M,Mclaughlin V,et al.Beraprost therapy for pulmonary arterial hypertension[J].J Am Coll Cardiol,2003,41:2119-2125.
  • 8Barst RJ,McGoon M,McLaughlin V,et al.Beraprost therapy for pulmonary arterial hypertension[J].J Am Coll Cardiol,2003,41:2119-2125.
  • 9Channick RN,Simonneau G,Sitbon O,et al.Effects of the dual endothelin-receptor antagonistbosentan in patients with pulmonary hypertension:a randomised placebo-controlled study[J].Lancet,2001,358:1119-1123.
  • 10Rubin LJ,Badesch DB,Barst RJ,et al.Bosentan therapy for pulmonary arterial hypertension[J].N Engl J Med,2002,346:896-903.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部